Intentar ORO - Gratis
Devising a viable global strategy to combat Cholera
BioSpectrum Asia
|BioSpectrum Asia June 2023
Since mid-2021, the world is facing an acute upsurge of the 7th cholera pandemic characterised by the number, size and concurrence of multiple outbreaks, the spread to areas free of cholera for decades and alarming high mortality rates. Based on the current situation and lack of vaccines and other resources, the World Health Organisation (WHO) assesses the risk at the global level as very high.
-

For reasons not yet fully understood, beginning in 2022 the world experienced an unprecedented surge in cholera outbreaks as characterised by the number, size and concurrence. Cholera is an acute, rapidly dehydrating diarrheal disease transmitted through water or food contaminated with the bacteria Vibrio cholerae O1. It is a disease of poverty, primarily affecting people living in areas without access to safe drinking water and inadequate sanitation.
The global burden of cholera is not fully known because of under-reporting, with some affected countries not reporting cases at all to avoid the stigma. One study estimates 1.3 billion people are at risk for cholera in a total of 69 endemic countries, with 2.86 million cholera cases and an estimated 95,000 deaths annually. Most of the global burden is in sub-Saharan Africa (60 per cent ) and South-East Asia (29 per cent ).
In January 2023, WHO declared cholera to be a grade 3 global emergency, the highest risk level. As of March, there were 24 countries reporting outbreaks, a number expected to increase as most countries are not yet in the high transmission season. The Steering Committee of the Global Task Force on Cholera Control (GTFCC) issued a statement that climate change multiplies the risk of cholera around the world, and the upsurge beginning in 2022 may be the new normal.
Esta historia es de la edición BioSpectrum Asia June 2023 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size